Rituximab for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA174
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1

Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide is considered appropriate.

1.2

Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia.

  • National Institute for Health and Care Excellence (NICE)